| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_79f0a9cf228ec5df422294a38aa0c896 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1641
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30 |
| filingDate |
1997-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fd5b3c94116c0922ec21b0aef685a61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63e4c1f35e81fa1cc5c3ee7d59fc7219 |
| publicationDate |
2004-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1424069-A2 |
| titleOfInvention |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| abstract |
Controlled-release oral drug dosage forms that comprise a tablet or capsulencontaining a plurality of particles of a solid-state drug dispersed in answellable/erodible polymer, such as poly(ethylene oxide) are described. Onceningested, the tablet or capsule disintegrates to disperse the particles within thenstomach where they imbibe water to cause them to swell and promote retention innfed-mode-induced patients. As the gastric-retained dosage form gradually erodes, thendrug is released in a controlled manner to the stomach for treatment of localndisorders, and to the upper gastrointestinal tract where it becomes available fornabsorption in a controlled and therapeutic manner. Drug containing vesicles, such asnliposomes or nanoparticles or enteric-coated drugs particles, can also be delivered tonthe gastrointestinal tract in a controlled manner using the gastric-retentive dosagenforms of the present invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10835488-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1843755-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1843755-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006084164-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10076494-B2 |
| priorityDate |
1996-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |